LGD-4033 Ligandrol SARM Guide: Research, Uses and Cycle Information

LGD-4033, Ligandrol and VK5211 are names used for the same investigational selective androgen receptor modulator. It has been evaluated in controlled human studies involving lean body mass, physical function and recovery from muscle loss.

What Is LGD-4033 Ligandrol?

LGD-4033 is a nonsteroidal selective androgen receptor modulator, commonly abbreviated as a SARM. Ligandrol is its familiar market name, while VK5211 is the development name used by Viking Therapeutics.

The compound was investigated as a possible treatment for conditions involving reduced muscle mass and impaired physical function. It remains investigational and has not been approved as a general muscle-building or performance-enhancing medicine.

How Does LGD-4033 Work?

LGD-4033 binds to and activates androgen receptors. These receptors influence muscle, bone and other androgen-responsive tissues.

The aim behind SARM development was to investigate whether anabolic activity in muscle and bone could be separated from some of the broader effects associated with traditional androgenic compounds. The word selective does not mean that LGD-4033 acts only in muscle or that hormonal effects elsewhere are impossible.

Published Human Research on LGD-4033

A randomized, double-blind and placebo-controlled study evaluated LGD-4033 in 76 healthy men between 21 and 50 years old. Participants received placebo or 0.1 mg, 0.3 mg or 1 mg of LGD-4033 daily for 21 days.

The researchers reported a dose-related increase in lean body mass during the three-week study. Fat mass did not change significantly, meaning that the study should not be interpreted as evidence that LGD-4033 directly produces fat loss.

The study also measured muscle strength and stair-climbing performance. Its short duration and relatively small participant groups limited the conclusions that could be drawn about functional performance or longer-term outcomes.

The study amounts were substantially lower than many amounts discussed in non-medical performance communities. Results from the controlled trial cannot automatically be transferred to higher amounts or longer cycles.

Hormonal Findings in the 21-Day Study

LGD-4033 produced dose-related changes in several hormonal measurements. Total testosterone and sex hormone-binding globulin decreased as exposure increased, while free testosterone and follicle-stimulating hormone showed significant suppression in the 1 mg group.

These findings show that hormonal effects can occur even during a relatively short research period. A short cycle should therefore not automatically be described as non-suppressive.

The researchers followed participants for five weeks after treatment and reported that the measured hormone levels returned to baseline after LGD-4033 was discontinued. This controlled study result does not guarantee the same recovery pattern after higher exposure, longer use or combinations involving several compounds.

LGD-4033 and Cholesterol Measurements

The published study also reported dose-related reductions in high-density lipoprotein cholesterol and triglycerides. Total cholesterol and low-density lipoprotein cholesterol did not change significantly during the trial.

This is another reason the research should not be reduced to lean-mass results alone. Hormonal, lipid and other laboratory measurements provide important context when reviewing the compound’s overall research profile.

VK5211 Research After Hip-Fracture Surgery

LGD-4033 was later developed under the name VK5211 for research involving people recovering from hip-fracture surgery. Viking Therapeutics reports that 108 participants received placebo or one of three VK5211 amounts for 12 weeks.

The company reported statistically significant increases in lean body mass across the VK5211 groups compared with placebo. Certain physical-performance measurements also showed numerical improvements, although those exploratory endpoints were not designed to establish statistical significance.

These results were reported by the developing company and should be distinguished from the peer-reviewed 21-day study in healthy men. The hip-fracture population and research amounts also differ from non-medical bodybuilding use.

Why LGD-4033 Is Discussed for Lean Mass

LGD-4033 became popular within the performance market largely because controlled research reported increases in lean body mass over relatively short study periods.

This has led to its frequent inclusion in discussions about lean mass, bulking and body recomposition. However, an increase in measured lean body mass does not guarantee a specific increase in visible muscle, strength or athletic performance for every person.

Training, nutrition, total calorie intake, previous experience and individual response remain important influences on body composition.

Common LGD-4033 Cycle Discussions

Non-medical SARM communities commonly discuss LGD-4033 cycles lasting several weeks and using amounts that exceed those evaluated in the published 21-day study.

These community patterns are not clinically validated protocols. The principal peer-reviewed study used no more than 1 mg daily, while the later company-reported VK5211 trial used amounts ranging from 0.5 mg to 2 mg daily.

Research findings from those controlled studies should not be used to claim that higher performance-market amounts will produce proportionally greater results or retain the same tolerability profile.

Does LGD-4033 Require PCT?

The published 21-day trial recorded dose-related suppression of total testosterone, with additional hormonal changes at the highest studied amount. This provides direct evidence that LGD-4033 can affect normal hormonal signalling.

The degree of suppression and recovery can vary according to the amount used, cycle duration, previous exposure, use of other compounds and individual hormone levels. Cycle length alone cannot reliably determine whether post-cycle support is appropriate.

Blood testing before and after a cycle provides more useful information than relying only on symptoms or applying the same PCT plan automatically.

Available options can be compared in the SARM PCT and Post-Cycle Support category. Enclomiphene, Clomid, Nolvadex, Arimidex and HCG work through different mechanisms and should not be treated as interchangeable products.

LGD-4033 Compared With Ostarine

LGD-4033 and Ostarine are both genuine selective androgen receptor modulators, but they are separate compounds with different clinical-development histories.

Ostarine MK-2866, also known as enobosarm, has been studied across several medical populations. LGD-4033 has a smaller published evidence base, although its controlled human study reported measurable lean-mass changes after only 21 days.

The products also have different concentrations. The Sarms Thailand LGD-4033 product contains 10 mg per ml, while the Ostarine product contains 25 mg per ml. Concentration alone does not make one compound stronger, safer or more suitable than another.

LGD-4033 Compared With RAD-140

LGD-4033 and RAD-140 both interact with androgen receptors, but they are not different names for the same compound.

LGD-4033 has published placebo-controlled research in healthy men. RAD-140 has a different research history and should be evaluated through its own product and compound information rather than assuming that the two SARMs have identical effects.

Both products can be compared through the Liquid SARMs in Thailand category.

LGD-4033 in SARM Stacks

LGD-4033 appears in several pre-built combinations, including packages positioned around lean mass and bulking. Some of these stacks also contain RAD-140, S-4 or MK-677.

MK-677 is not a SARM and works through a different biological pathway. Combining LGD-4033 with additional products creates a more complex cycle than using one compound alone, so each included product should be evaluated separately.

Current combinations can be reviewed in the SARM Stacks in Thailand category.

LGD-4033 Research Status

LGD-4033 remains an investigational compound. Human studies have evaluated its effects on lean body mass and physical function, but it is not approved as a general bodybuilding, bulking or athletic-performance medicine.

LGD-4033, also listed as Ligandrol, is prohibited under the World Anti-Doping Agency Prohibited List. Athletes subject to anti-doping testing should avoid products containing LGD-4033, Ligandrol or VK5211.

Frequently Asked Questions

Are LGD-4033, Ligandrol and VK5211 the same compound?

Yes. LGD-4033 is the research code, Ligandrol is the familiar market name and VK5211 is the development name associated with the same compound.

Is LGD-4033 a real SARM?

Yes. LGD-4033 is a nonsteroidal selective androgen receptor modulator. This distinguishes it from Cardarine and MK-677, which are often grouped with SARMs commercially but belong to different compound classes.

What did the published LGD-4033 human study find?

The 21-day placebo-controlled study reported dose-related increases in lean body mass. It also recorded dose-related changes in testosterone, sex hormone-binding globulin and high-density lipoprotein cholesterol.

Did LGD-4033 reduce body fat in the human study?

No significant change in fat mass was reported during the published 21-day trial. The lean-mass findings should not be presented as proof of direct fat loss.

How much LGD-4033 is in 1 ml?

In a liquid containing 10 mg per ml, one full millilitre contains 10 mg of LGD-4033.

Does every LGD-4033 cycle require PCT?

No single answer applies to every cycle. The amount, duration, other compounds used and individual hormonal response all matter. Relevant blood testing provides clearer information than cycle length alone.

Can LGD-4033 be combined with other SARMs?

LGD-4033 is included in several commercially available stacks, but combining compounds increases complexity. Each product has its own mechanism, concentration and research profile and should be considered separately.

LGD-4033 Research Sources

• Full text of the placebo-controlled LGD-4033 study in healthy men
• PubMed record for the 21-day LGD-4033 study
• Viking Therapeutics VK5211 development and Phase 2 summary
• PubChem information for LGD-4033 and VK5211
• World Anti-Doping Agency Prohibited List